Yongheng Shi Selected Research

Necrosis

1/2021

The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yongheng Shi Research Topics

Disease

4	Neoplasms (Cancer) 01/2021 - 10/2017
3	Hyperlipidemias (Hyperlipidemia) 01/2022 - 01/2021
2	Inflammation (Inflammations) 01/2022 - 01/2021
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 10/2017
1	Hypertension (High Blood Pressure) 04/2024
1	Autoimmune Diseases (Autoimmune Disease) 04/2024
1	Prostatic Neoplasms (Prostate Cancer) 01/2023
1	Cardiovascular Diseases (Cardiovascular Disease) 12/2022
1	Necrosis 01/2021
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2020
1	Interstitial Lung Diseases (Interstitial Lung Disease) 05/2020
1	Gallbladder Neoplasms (Gallbladder Cancer) 12/2019
1	Lymphoma (Lymphomas) 12/2017
1	Neoplasm Metastasis (Metastasis) 10/2017
1	Type 2 Diabetes Mellitus (MODY) 05/2014

Drug/Important Bio-Agent (IBA)

3	tyloxapol FDA Link 01/2022 - 01/2021
2	Triglycerides (Triacylglycerol)IBA 01/2022 - 12/2021
2	Clofibrate FDA Link 01/2022 - 01/2021
2	CholesterolIBA 01/2022 - 12/2021
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2017
1	Prostaglandin H2 Thromboxane A2 ReceptorsIBA 04/2024
1	Immunosuppressive Agents (Immunosuppressants)IBA 04/2024
1	ResveratrolIBA 04/2024
1	Sirtuin 1IBA 04/2024
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 04/2024
1	Endothelin Receptors (Endothelin Receptor)IBA 12/2022
1	Fenofibrate (CiL)FDA LinkGeneric 12/2021
1	LipidsIBA 12/2021
1	sesaminIBA 12/2021
1	sesamolIBA 01/2021
1	Hypolipidemic Agents (Antihyperlipidemics)IBA 01/2021
1	AntioxidantsIBA 01/2021
1	Clofibric AcidIBA 01/2021
1	MethyltransferasesIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Long Noncoding RNAIBA 10/2020
1	Gefitinib (Iressa)FDA Link 05/2020
1	osimertinibIBA 05/2020
1	anlotinibIBA 05/2020
1	cabozantinibIBA 05/2020
1	Tyrosine Kinase InhibitorsIBA 05/2020
1	Explosive Agents (Explosives)IBA 05/2020
1	Gemcitabine FDA Link 12/2019
1	Transcription Factors (Transcription Factor)IBA 01/2018
1	Phosphotransferases (Kinase)IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	Formaldehyde (Formol)FDA Link 01/2018
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018
1	ParaffinIBA 01/2018
1	Chemokine ReceptorsIBA 12/2017
1	MicroRNAs (MicroRNA)IBA 10/2017
1	Sodium-Glucose Transporter 2 InhibitorsIBA 05/2014
1	1- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 1,6- dideoxyglucopyranoseIBA 05/2014
1	Glucose (Dextrose)FDA LinkGeneric 05/2014
1	SodiumIBA 05/2014

Therapy/Procedure

1	Therapeutics 01/2023